5.99
0.77 (14.75%)
Previous Close | 5.22 |
Open | 5.29 |
Volume | 661,206 |
Avg. Volume (3M) | 481,209 |
Market Cap | 338,040,832 |
Price / Book | 1.74 |
52 Weeks Range | |
Earnings Date | 11 Aug 2025 - 15 Aug 2025 |
Diluted EPS (TTM) | -1.88 |
Total Debt/Equity (MRQ) | 1.75% |
Current Ratio (MRQ) | 17.39 |
Operating Cash Flow (TTM) | -96.14 M |
Levered Free Cash Flow (TTM) | -62.11 M |
Return on Assets (TTM) | -22.56% |
Return on Equity (TTM) | -32.89% |
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Bearish | Bearish |
Biotechnology (Global) | Bearish | Bearish | |
Stock | Astria Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
Analyst Consensus | 5.0 |
Insider Activity | NA |
Price Volatility | 0.5 |
Technical Moving Averages | 0.0 |
Technical Oscillators | 2.0 |
Average | 1.88 |
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Core |
% Held by Insiders | 0.49% |
% Held by Institutions | 104.13% |
52 Weeks Range | ||
Price Target Range | ||
High | 47.00 (Cantor Fitzgerald, 684.64%) | Buy |
Median | 31.50 (425.88%) | |
Low | 16.00 (HC Wainwright & Co., 167.11%) | Buy |
Average | 31.50 (425.88%) | |
Total | 2 Buy | |
Avg. Price @ Call | 4.98 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
HC Wainwright & Co. | 13 Jun 2025 | 16.00 (167.11%) | Buy | 5.99 |
Cantor Fitzgerald | 14 May 2025 | 47.00 (684.64%) | Buy | 3.97 |
29 Apr 2025 | 47.00 (684.64%) | Buy | 5.12 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |